{"id":101173,"name":"UNITED STATES PHARMACOPEIAL CONVENTION","slug":"united-states-pharmacopeial-convention","state":"MD","description":"Organization that sets standards for medicines, food ingredients, and dietary supplements.","totalSpending":1340000,"filings":24,"yearlySpending":[{"year":2018,"income":290000},{"year":2019,"income":300000},{"year":2020,"income":150000},{"year":2021,"income":160000},{"year":2022,"income":130000},{"year":2024,"income":210000},{"year":2025,"income":100000}],"firms":["AKIN GUMP STRAUSS HAUER & FELD"],"lobbyists":["NATHAN BROWN","HEIDE BAJNRAUH","MATTHEW TUTEN","SEAN FEELY","MARIO RAMIREZ","ANNA ABRAM","KANDIS MCCLURE"],"issues":["HCR","PHA","DEF"],"sampleDescriptions":["FDA and NIH Workforce Authorities Modernization Act; FDA User Fee re authorization legislation; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; OTC monograph legislation; compounding; opioids.","H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; OTC monograph legislation; compounding; opioids.","OTC monograph legislation; compounding; opioids; dietary supplements; 2020 Agricultural FDA appropriations legislation.","Compounding; 2020 Agricultural FDA appropriations legislation; Lower Health Care Costs Act (s.1895); Drug Pricing.","Compounding; 2020 Agricultural FDA appropriations legislation; Lower Health Care Costs Act (s.1895); Drug Pricing; Cures 2.0.","Compounding; Drug Pricing; Cures 2.0; Lower Health Care Costs Act; CARES Act; Additional COVID-19 relief legislation; HEROES Act; National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act; COVID-19 pandemic response","Compounding; Drug Pricing; Cures 2.0; CARES Act (S. 3548/H.R. 748); Additional COVID-19 pandemic response legislation; HEROES Act (H.R. 6800); National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act (H.R. 4866); FY 2021 appropriations; Health, Economic Assistance, Liability Protection and Schools (HEALS) Act.","Compounding; Lower Health Care Costs Act (S.1895); Drug Pricing; 21st Century Cures Act 2.0; CARES Act (S. 3548/H.R. 748); COVID-19 pandemic response; HEROES Act (H.R. 6800); National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act (H.R. 4866); Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; FY 2021 Consolidated Appropriations Act (H.R. 133)","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations Act (H.R. 133).","Compounding; Drug pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations.","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations; Cannabis.","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations; Cannabis; Infrastructure and budget reconciliation legislation.","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2023 Appropriations; Infrastructure and budget reconciliation legislation; advanced manufacturing technologies.","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2023 Appropriations; Infrastructure and budget reconciliation legislation.","Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2023 Appropriations; Infrastructure and budget reconciliation legislation; advanced manufacturing technologies; medical supply chain; FDA user fee legislation.","Medical supply chain issues and supply chain integrity; advanced manufacturing; cannabis.","Issues related to drug quality testing.","PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); Pharmaceutical supply chain issues, S. 2364 - Mapping America's Pharmaceutical Supply Act; drug shortages.","PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); Pharmaceutical supply chain issues, S. 2364 - Mapping America's Pharmaceutical Supply Act; S.2589 - Drug Shortage Prevention and Quality Improvement Act.","Pharmaceutical and supply chain; drug quality and drug testing."],"years":[2018,2019,2020,2021,2022,2024,2025]}